Status:
ACTIVE_NOT_RECRUITING
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Lead Sponsor:
Nanoscope Therapeutics Inc.
Conditions:
Retinitis Pigmentosa
Retinitis
Eligibility:
All Genders
18+ years
Brief Summary
This study will be conducted following Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines. Eligible subjects will be consented to return for scheduled study vi...
Detailed Description
This study is designed to follow subjects with Retinitis Pigmentosa (RP) previously enrolled in study NTXMCO-002 (RESTORE, NCT04945772). In that study, 18 of 27 enrolled subjects received MCO-010, an ...
Eligibility Criteria
Inclusion
- Previously enrolled in study NTXMCO-002 (RESTORE)
- Able to comprehend and give informed consent.
- Able to comply with testing and all protocol tests.
- Agree to participate for the full 3-year duration of follow-up to the best of their ability and barring any unforeseen circumstances.
Exclusion
- Not applicable. Subjects will be included in this study and will be consented after completion of all assessments at their final RESTORE study visit
Key Trial Info
Start Date :
December 8 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2027
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06162585
Start Date
December 8 2023
End Date
September 1 2027
Last Update
March 24 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanoscope Clinical Site
Beverly Hills, California, United States, 90211
2
Nanoscope Clinical Site
Pensacola, Florida, United States, 32503
3
Nanoscope Clinical Site
Fargo, North Dakota, United States, 58103
4
Nanoscope Clinical Site
Houston, Texas, United States, 77030